Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Drops By 61.9%

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 10,835 shares, a drop of 61.9% from the November 30th total of 28,413 shares. Based on an average daily trading volume, of 7,085 shares, the days-to-cover ratio is currently 1.5 days. Based on an average daily trading volume, of 7,085 shares, the days-to-cover ratio is currently 1.5 days.

Algernon Pharmaceuticals Price Performance

AGNPF opened at $0.06 on Friday. The stock’s 50 day moving average price is $0.06 and its 200-day moving average price is $0.05. Algernon Pharmaceuticals has a 52-week low of $0.04 and a 52-week high of $0.09.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).